Abstract
We reported a novel, high CNS (central nervous system) penetrance pan-ERBB inhibitor, NT-113, for anti-glioma therapy. Using five intracranial glioblastoma (GBM) models, we found that NT-113 significantly suppresses growth of tumors overexpressing wild-type EGFR or the EGFRvIII mutant, resulting in improved animal survival. NT-113 inhibits ERBB activity at low nanomolar (< 5 nM) concentrations, and suppresses its downstream signaling through Akt, leading to reduced cell proliferation and increased apoptosis. When compared with previous generations of EGFR small tyrosine kinase inhibitors (TKIs), erlotinib and lapatanib, NT-113 shows the most substantial effect on tumor growth inhibition and animal survival. The superior anti-glioma activity of NT-113 can be explained by broader spectrum of ERBB inhibition, efficient brain penetrance, and superior tumor uptake. Our data support clinical investigation of NT-113 in glioma over-expressing wild type or vIII forms of EGFR.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
